Selected Adverse Events
Selected** adverse reactions in patients who received MYLOTARG in combination therapy study (ALFA-0701)1
The most frequent (≥ 1%) adverse reactions that led to permanent discontinuation in the combination therapy study were thrombocytopenia, VOD, haemorrhage and infection
The rate of infection was similar with MYLOTARG™ + chemotherapy vs chemotherapy alone
- MYLOTARG™ + chemotherapy arm:
- All-causality severe (Grade ≥ 3) infections were reported in 102 (77.9%) patients
- Treatment-related death due to septic shock was reported in 1 (0.8%) patients
- MYLOTARG™ + chemotherapy and chemotherapy alone arm:
- Fatal severe infection was reported in 2 (1.5%) patients in the MYLOTARG™ + chemotherapy arm and 4 (2.9%) patients in the chemotherapy alone arm
*Including fatal outcome
**Only selected safety data were collected in this study of newly diagnosed AML
Reference
PP-MYL-GBR-0093. December 2019
Selected** adverse reactions in patients who received MYLOTARG in combination therapy study (ALFA-0701)1
The most frequent (≥ 1%) adverse reactions that led to permanent discontinuation in the combination therapy study were thrombocytopenia, VOD, haemorrhage and infection
VOD was a common (≥ 1%) adverse event with MYLOTARG™ + chemotherapy vs chemotherapy alone
- MYLOTARG™ + chemotherapy and chemotherapy alone arm:
- Six (4.6%) patients in the MYLOTARG™ + chemotherapy arm and 2 (1.5%) patients in the chemotherapy alone arm experienced VOD
- Two (1.5%) patients in the MYLOTARG™ + chemotherapy arm died owing to VOD
- The two VOD events in the chemotherapy arm occurred after MYLOTARG™ re-treatment for relapse
*Including fatal outcome.
**Only selected safety data were collected in this study of newly diagnosed AML
VOD, veno-occlusive disease.
Reference
PP-MYL-GBR-0095. December 2019
Selected** adverse reactions in patients who received MYLOTARG in combination therapy study (ALFA-0701)1
The most frequent (≥ 1%) adverse reactions that led to permanent discontinuation in the combination therapy study were thrombocytopenia, VOD, haemorrhage and infection
The rate of haemorrhage was higher with MYLOTARG™ + chemotherapy vs chemotherapy alone
- MYLOTARG™ + chemotherapy arm:
- The most frequent Grade 3 bleeding/haemorrhagic reactions were haematemesis (3.1%), haemoptysis (3.1%) and haematuria (2.3%)
- Grade 4 bleeding/haemorrhagic reactions were reported in 4 (3.1%) patients (gastrointestinal haemorrhage, haemorrhage and pulmonary alveolar haemorrhage [2 patients])
- Fatal bleeding/haemorrhagic reactions were reported in 3 (2.3%) patients (cerebral haematoma, intracranial haematoma and subdural haematoma)
*Including fatal outcome.
**Only selected safety data were collected in this study of newly diagnosed AML
Reference
PP-MYL-GBR-0307. November 2020
Selected** adverse reactions in patients who received MYLOTARG in combination therapy study (ALFA-0701)1
The most frequent (≥ 1%) adverse reactions that led to permanent discontinuation in the combination therapy study were thrombocytopenia, VOD, haemorrhage and infection
Severe persistent thrombocytopenia* was observed in 22 (20.4%) patients in the MYLOTARG™ + chemotherapy arm
- MYLOTARG™ + chemotherapy arm:
- The median time to recovery of platelets following induction was 34 days
*Thrombocytopenia with platelet counts < 50,000/mm3 persisting 45 days after the start of therapy for responding patients (CR and CRp).
**Only selected safety data were collected in this study of newly diagnosed AML
CR, complete remission; CRp, complete remission with incomplete platelet recovery.
Reference
PP-MYL-GBR-0094. December 2019